Solvias Research Team Receives Sandmeyer Award 2012

The Swiss Chemical Society has awarded the Sandmeyer Award 2012 to a research team from Solvias. Working for Sanofi Pasteur, the team developed an innovative, efficient and fully synthetic process for protoporphyrin IX, a precursor of hemoglobin.

The research team is made up of Dr. Dirk Spielvogel, Dr. Dietmar Flubacher, Dr. Andreas Boudier, Markus Müller and Dr. Pierre Martin from the Chemical Development and Catalysis department at Solvias.

Protoporphyrin IX is an essential co-factor in the biotechnological vaccine production process at Sanofi Pasteur. Changes to the law relating impurities of animal origin made it impossible to use this substance, which is extracted from blood. However, the researchers found an effective alternative in just a few months: they developed a fully synthetic means of access, which resulted - among other things - in the first substance samples for biotechnological process validation. Thanks to these efforts, the team entered new conceptual territory in the synthesis of porphyrins.

The award is sponsored by KPMG.

 

Company

Solvias AG

Im Römerpark 2
4303 Kaiseraugst
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read